In this controversy series, here are outlined the pros and cons regarding the use of flumazenil in acute benzodiazepine toxicity with regard to the following categories: safety, efficacy/cost-effectiveness and practicality of use.
After reading our brief summary of the evidence we will present clinical scenarios for which your input is requested.
We will collect answers for one week and post the results on our site to reflect the clinical toxicology community’s practice patterns.
There is no right or wrong answers in the questions we ask. We are primarily interested in assessing potential variability in practice and underlying reasons.